Catalyst Wire Dossier Catalyst Wire Dossier

TAK-438 (vonoprazan)

vonoprazan · Takeda Pharmaceutical Company
Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for TAK-438 (vonoprazan), covering 2013-07-03 to 2014-02-10. Get the full timeline:

Most recent: Clinical Trial Update: A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy [Phase 3]

See pricing